Journal of the American Society of Nephrology, Vol 4, 40-49, Copyright © 1993 by American Society of Nephrology

REGULAR ARTICLES

Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes

A Remuzzi, N Perico, CS Amuchastegui, B Malanchini, M Mazerska, C Battaglia, T Bertani and G Remuzzi
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.

The short- and long-term effects of specific angiotensin II (AII) receptor blockade on the evaluation of glomerular injury in moderately hyperglycemic diabetic rats were studied. Three groups of animals were used, a control group, a group of diabetic rats treated with insulin, and a group of insulin-treated diabetic rats receiving the AII receptor antagonist losartan in drinking water. After 4 to 6 wk of observation, diabetic rats showed higher systolic blood pressure and GFR than normal controls. Losartan treatment prevented both systolic blood pressure and GFR rise. Three other groups of rats, similarly treated for a 1-yr period, were used for renal functional and morphologic evaluation. Diabetic animals had higher urinary protein excretion and glomerulosclerosis incidence than did normal controls. Losartan significantly prevented proteinuria and glomerulosclerosis. Evaluation of the sieving properties of the glomerular membrane by Ficoll fractional clearance showed an important increase in the filtration of this marker in diabetic animals, as compared with that in controls, and almost complete prevention of this change in losartan-treated animals. Theoretical analysis of fractional clearance data with a heteroporous model of glomerular size-selectivity showed that in diabetic animals the size of membrane pores was increased uniformly, as compared with that in controls. These changes were completely prevented by the AII receptor antagonist. The results presented here strongly indicate that reduction of AII activity plays a crucial role in the preservation of glomerular structure and function and suggest that the favorable effects previously observed with angiotensin-converting enzyme inhibition in this model depend directly on the reduction of AII activity.

This article has been cited by other articles:

				Z.-G. Xu, H. Yuan, L. Lanting, S.-L. Li, M. Wang, N. Shanmugam, M. Kato, S. G. Adler, M. A. Reddy, and R. Natarajan Products of 12/15-Lipoxygenase Upregulate the Angiotensin II Receptor J. Am. Soc. Nephrol., March 1, 2008; 19(3): 559 - 569. [Abstract] [Full Text] [PDF]

				K. Suzuki, G. D. Han, N. Miyauchi, T. Hashimoto, T. Nakatsue, Y. Fujioka, H. Koike, F. Shimizu, and H. Kawachi Angiotensin II Type 1 and Type 2 Receptors Play Opposite Roles in Regulating the Barrier Function of Kidney Glomerular Capillary Wall Am. J. Pathol., June 1, 2007; 170(6): 1841 - 1853. [Abstract] [Full Text] [PDF]

				A. K. Bidani, M. Picken, R. Hacioglu, G. Williamson, and K. A. Griffin Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance Am J Physiol Renal Physiol, February 1, 2007; 292(2): F647 - F654. [Abstract] [Full Text] [PDF]

				C. Guo, D. Martinez-Vasquez, G. P. Mendez, M. F. Toniolo, T. M. Yao, E. M. Oestreicher, T. Kikuchi, N. Lapointe, L. Pojoga, G. H. Williams, et al. Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus Endocrinology, November 1, 2006; 147(11): 5363 - 5373. [Abstract] [Full Text] [PDF]

				Y. Tabel, A. Berdeli, S. Mir, E. Serdaroglu, and E. Ytlmaz Effects of Genetic Polymorphisms of the Renin-Angiotensin System in Children with Nephrotic Syndrome Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 138 - 144. [Abstract] [PDF]

				D. Venturoli and B. Rippe Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability Am J Physiol Renal Physiol, April 1, 2005; 288(4): F605 - F613. [Abstract] [Full Text] [PDF]

				I. Codreanu, N. Perico, and G. Remuzzi Dual Blockade of the Renin-Angiotensin System: The Ultimate Treatment for Renal Protection? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S34 - S38. [Abstract] [Full Text] [PDF]

				B. E. Thomas and T. J. Thekkumkara Glucose Mediates Transcriptional Repression of the Human Angiotensin Type-1 Receptor Gene: Role for a Novel Cis-acting Element Mol. Biol. Cell, October 1, 2004; 15(10): 4347 - 4355. [Abstract] [Full Text] [PDF]

				A. Erman, S. Veksler, U. Gafter, G. Boner, C. Wittenberg, and D. J. van Dijk Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor {beta}1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 146 - 151. [Abstract] [PDF]

				S. Nomura, A. Shouzu, S. Omoto, M. Nishikawa, and T. Iwasaka Effects of Losartan and Simvastatin on Monocyte-Derived Microparticles in Hypertensive Patients With and Without Type 2 Diabetes Mellitus Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 133 - 141. [Abstract] [PDF]

				R. M. Mason and N. A. Wahab Extracellular Matrix Metabolism in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1358 - 1373. [Abstract] [Full Text] [PDF]

				J. Segura, M. Praga, C. Campo, J. L Rodicio, and L. M Ruilope Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 43 - 47. [Abstract] [PDF]

				C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, D. Rottoli, C. Batani, C. Zanchi, M. Abbate, and G. Remuzzi How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2898 - 2908. [Abstract] [Full Text] [PDF]

				G. Viberti, N. M. Wheeldon, and for the MicroAlbuminuria Reduction With VALsartan Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure-Independent Effect Circulation, August 6, 2002; 106(6): 672 - 678. [Abstract] [Full Text] [PDF]

				G. Remuzzi, P. Ruggenenti, and N. Perico Chronic Renal Diseases: Renoprotective Benefits of Renin-Angiotensin System Inhibition Ann Intern Med, April 16, 2002; 136(8): 604 - 615. [Abstract] [Full Text] [PDF]

				Y. Suzuki, O. Lopez-Franco, D. Gomez-Garre, N. Tejera, C. Gomez-Guerrero, T. Sugaya, R. Bernal, J. Blanco, L. Ortega, and J. Egido Renal Tubulointerstitial Damage Caused by Persistent Proteinuria Is Attenuated in AT1-Deficient Mice : Role of Endothelin-1 Am. J. Pathol., November 1, 2001; 159(5): 1895 - 1904. [Abstract] [Full Text] [PDF]

				W. M. Deen, M. J. Lazzara, and B. D. Myers Structural determinants of glomerular permeability Am J Physiol Renal Physiol, October 1, 2001; 281(4): F579 - F596. [Abstract] [Full Text] [PDF]

				G. J. Wehbi, J. Zimpelmann, R. M. Carey, D. Z. Levine, and K. D. Burns Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors Am J Physiol Renal Physiol, February 1, 2001; 280(2): F254 - F265. [Abstract] [Full Text] [PDF]

				B. M Brenner, M. E Cooper, D. de Zeeuw, J.-P. Grunfeld, W. F Keane, K. Kurokawa, J. B McGill, W. E Mitch, H. H. Parving, G. Remuzzi, et al. The losartan renal protection study -- rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 328 - 335. [Abstract] [PDF]

				P. C. Deedwania Hypertension and Diabetes: New Therapeutic Options Arch Intern Med, June 12, 2000; 160(11): 1585 - 1594. [Abstract] [Full Text] [PDF]

				S. Kim and H. Iwao Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases Pharmacol. Rev., March 1, 2000; 52(1): 11 - 34. [Abstract] [Full Text] [PDF]

				G. C. Schoonmaker, R. W. Fallet, and P. K. Carmines Superoxide anion curbs nitric oxide modulation of afferent arteriolar ANG II responsiveness in diabetes mellitus Am J Physiol Renal Physiol, February 1, 2000; 278(2): F302 - F309. [Abstract] [Full Text] [PDF]

				C. Tschope, A. Reinecke, U. Seidl, M. Yu, V. Gavriluk, U. Riester, P. Gohlke, K. Graf, M. Bader, U. Hilgenfeldt, et al. Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2333 - H2340. [Abstract] [Full Text] [PDF]

				A. Edwards, B. S. Daniels, and W. M. Deen Ultrastructural model for size selectivity in glomerular filtration Am J Physiol Renal Physiol, June 1, 1999; 276(6): F892 - F902. [Abstract] [Full Text] [PDF]

				M. A. Moore, M. Epstein, L. Agodoa, and L. D. Dworkin Current Strategies for Management of Hypertensive Renal Disease Arch Intern Med, January 11, 1999; 159(1): 23 - 28. [Abstract] [Full Text] [PDF]

				K. Sharma, L. Wang, Y. Zhu, A. DeGuzman, G.-Y. Cao, R. B. Lynn, and S. K. Joseph Renal type I inositol 1,4,5-trisphosphate receptor is reduced in streptozotocin-induced diabetic rats and mice Am J Physiol Renal Physiol, January 1, 1999; 276(1): F54 - F61. [Abstract] [Full Text] [PDF]

				G. R. Bolton, W. M. Deen, and B. S. Daniels Assessment of the charge selectivity of glomerular basement membrane using Ficoll sulfate Am J Physiol Renal Physiol, May 1, 1998; 274(5): F889 - F896. [Abstract] [Full Text] [PDF]

				S. Kim, H. Wanibuchi, A. Hamaguchi, K. Miura, S. Yamanaka, and H. Iwao Angiotensin Blockade Improves Cardiac and Renal Complications of Type II Diabetic Rats Hypertension, November 1, 1997; 30(5): 1054 - 1061. [Abstract] [Full Text]

				M. T. Velasquez Angiotensin II Receptor Blockers: A New Class of Antihypertensive Drugs Arch Fam Med, June 1, 1996; 5(6): 351 - 356. [Abstract] [PDF]

				N. K. Hollenberg and N. D. L. Fisher Renal Circulation and Blockade of the Renin-Angiotensin System : Is Angiotensin-Converting Enzyme Inhibition the Last Word? Hypertension, October 1, 1995; 26(4): 602 - 609. [Abstract] [Full Text]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673